BLACKCATCARD
12.8.2021 11:02:05 CEST | Business Wire | Press release
Blackcatcard is a money management service created with the goal of providing a state-of-the-art payments’ product for a global audience, without the limitation of jurisdictions.
The platform offers digital and physical Mastercard payment cards that can be accepted at any ATM or payment terminal that works with Mastercard. Each card is tied to a dedicated Euro IBAN account that is created for corporate and private users immediately upon completing a simple registration process. The creation of the account, the virtual and plastic cards, as well as card maintenance come free of charge for individuals.
Blackcatcard also provides an online payments’ solution for users to store their funds and an app to manage all cards, accounts and services. Card holders can not only store and transfer money between each other without any limitations or commissions, but also earn money via cashback and bonus programs.
These include an annual 2.2% interest program on your holdings, 0.1% cashback on all card purchases and a profitable referral program. All bonuses are credited as cash and are delivered to customers' accounts, which means that the customers can spend this money as they wish. Also the upcoming projects will be available soon, including the 5% cashback at the Play Market and 2% cashback at Amazon. The bonus payments system is part of the loyalty program provided by the partner FINTECH ASSETS OÜ . Detailed terms and conditions can be found here .
As a fun extra service Blackcatcard also offers cards with a nickname printed on them instead of the holder’s actual name. And there is also a Blackcatcard KIDS service for parents who want to give a card to their children. It comes with bright designs and has security options for adult oversight.
In addition to traditional fiat services, Blackcatcard offers cryptocurrency services as well. This service is rendered by a partner company DigiNord OÜ and is integrated into Blackcatcard. You can buy, sell, exchange, store and transact in a variety of cryptocurrencies. The crypto transfers between the Blackcatcard users do not have fees and limits. Due to the integration of the hot wallet into the same app as the IBAN account, the security standards meet the highest levels of regulation. It also cancels risks of losing passwords for the crypto wallet and does not require additional AML compliance for crypto transactions.
It is a modern-day solution for a modern society - freelancers, digital nomads, internet entrepreneurs, immigrants, students, travellers, people not covered by classic banking, and many others will find Blackcatcard’s services to be of great use in their daily lives.
About Blackcatcard
Blackcatcard is an international money management service that began in 2019 and is based in Europe with its teams' offices in Malta, Estonia, Serbia and other countries. It is issued by Papaya Ltd., licensed by the Malta Financial Services Authority as an Electronic Money Institution (EMI) with the registration number C55146. The service is available to clients and businesses, and places great emphasis on customer service and product features.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005290/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
